Hemogenyx Pharmaceuticals PLC (HEMO) - Cash Flow Conversion Efficiency

Latest as of December 2024: -2.090x

Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has a cash flow conversion efficiency ratio of -2.090x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.78 Million ≈ $-216.99 USD) by net assets (GBX853.49K ≈ $103.85 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HEMO net asset quality index to measure how much of total assets are equity-financed.

Hemogenyx Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Hemogenyx Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hemogenyx Pharmaceuticals PLC (HEMO) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Hemogenyx Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Aloro Mining Corp V:AORO	0.013x
CT UK High Income Trust Plc LSE:CHIB	0.007x
Cyanconnode Holdings PLC LSE:CYAN	-0.804x
Hawkeye Gold and Diamond Inc V:HAWK	0.031x
ROBUS GROUP AS EO -60 F:LH2	N/A
Angling Direct PLC LSE:ANG	0.059x
EGR EXPL LTD F:Z0R	-0.091x
Fashion Bel Air S.A PA:ALFBA	0.029x

Annual Cash Flow Conversion Efficiency for Hemogenyx Pharmaceuticals PLC (2015–2024)

The table below shows the annual cash flow conversion efficiency of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see HEMO market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX853.49K ≈ $103.85	GBX-4.12 Million ≈ $-500.91	-4.824x	-119.71%
2023-12-31	GBX2.78 Million ≈ $338.37	GBX-6.11 Million ≈ $-742.87	-2.195x	-144.66%
2022-12-31	GBX3.24 Million ≈ $394.64	GBX-2.91 Million ≈ $-354.14	-0.897x	-178.97%
2021-12-31	GBX8.17 Million ≈ $993.76	GBX-2.63 Million ≈ $-319.67	-0.322x	+84.34%
2020-12-31	GBX875.68K ≈ $106.55	GBX-1.80 Million ≈ $-218.81	-2.054x	-159.74%
2019-12-31	GBX-349.04K ≈ $-42.47	GBX-1.20 Million ≈ $-145.99	3.438x	+343.75%
2018-12-31	GBX959.17K ≈ $116.70	GBX-1.35 Million ≈ $-164.59	-1.410x	-563.74%
2017-12-31	GBX2.13 Million ≈ $259.39	GBX-452.98K ≈ $-55.11	-0.212x	+30.96%
2016-12-31	GBX903.71K ≈ $109.96	GBX-278.15K ≈ $-33.84	-0.308x	-30148.52%
2015-12-31	GBX77.82K ≈ $9.47	GBX79.71 ≈ $0.01	0.001x	--

About Hemogenyx Pharmaceuticals PLC

LSE:HEMO UK Biotechnology

Market Cap

$417.48K

GBX3.43 Billion GBX

Market Cap Rank

#30981 Global

#942 in UK

Share Price

GBX640.00

Change (1 day)

-2.14%

52-Week Range

GBX135.50 - GBX1545.00

All Time High

GBX1545.00